Back to Search
Start Over
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI
- Source :
- JAMA, The Journal of the American Medical Association. Oct 27, 2010, Vol. 304 Issue 16, p1821, 10 p.
- Publication Year :
- 2010
-
Abstract
- A literature search along with genetic study was conducted to define the risk of major adverse cardiovascular outcomes of reduced-function CYP2C19 genetic variants in patients treated with clopidogrel. The findings from meta-analysis demonstrated that common genetic variants in the CYP2C19 gene are associated with almost 1 in 3 patients not receiving ideal protection from ischemic events when treated with standard doses of clopidogrel for PCI.
Details
- Language :
- English
- ISSN :
- 00987484
- Volume :
- 304
- Issue :
- 16
- Database :
- Gale General OneFile
- Journal :
- JAMA, The Journal of the American Medical Association
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.242616734